{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T11:49:08Z","timestamp":1782647348861,"version":"3.54.5"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006370","name":"Small Business Innovation Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006370","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.neuropharm.2019.05.033","type":"journal-article","created":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T04:20:44Z","timestamp":1559017244000},"page":"107656","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"special_numbering":"C","title":["Personalizing dosing of risperidone, paliperidone and clozapine using therapeutic drug monitoring and pharmacogenetics"],"prefix":"10.1016","volume":"168","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7756-2314","authenticated-orcid":false,"given":"Jose","family":"de Leon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2019.05.033_bib1","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1046\/j.1365-2125.2003.01858.x","article-title":"Identification of a novel splice-site mutation in the CYP1A2 gene","volume":"56","author":"Allorge","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib2","doi-asserted-by":"crossref","DOI":"10.1097\/JCP.0000000000001050","article-title":"Gemfibrozil may decrease norclozapine elimination: a case report","author":"Barclay","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1055\/s-2005-873159","article-title":"Risperidone half-life in a patient taking paroxetine -- a case report","volume":"38","author":"Barnhill","year":"2005","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.033_bib4","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2125.1994.tb04385.x","article-title":"Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test","volume":"38","author":"Bertilsson","year":"1994","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib5","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4088\/JCP.v60n0709","article-title":"A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A","volume":"60","author":"Bork","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.033_bib6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/00007691-200502000-00019","article-title":"Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: evidence from a routine therapeutic drug monitoring service","volume":"27","author":"Castberg","year":"2005","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib7","author":"Cassels"},{"key":"10.1016\/j.neuropharm.2019.05.033_bib8","first-page":"599","article-title":"Clozapine dosages and plasma drug concentrations","volume":"96","author":"Chang","year":"1997","journal-title":"J. Formos. Med. Assoc."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib9","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00007691-199704000-00018","article-title":"Clinical evaluation and plasma clozapine concentrations in Chinese patients with schizophrenia","volume":"19","author":"Chong","year":"1997","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib10","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/0091217415621269","article-title":"Clozapine-induced myocarditis may be associated with rapid titration: a case report verified with autopsy","volume":"51","author":"Chopra","year":"2016","journal-title":"Int. J. Psychiatry Med."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib11","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/17512433.2019.1577134","article-title":"A comprehensive review of the swallowing difficulties and dysphagia in adults associated with antipsychotic","volume":"12","author":"Cicala","year":"2019","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib12","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3371\/CSRP.CI.101118","article-title":"Sustained-release risperidone via subcutaneous injection: a systematic review of RBP-7000 (PERSERIS (\u2122)) for the treatment of schizophrenia","volume":"12","author":"Citrome","year":"2018","journal-title":"Clin. Schizophrenia Relat. Psychoses"},{"key":"10.1016\/j.neuropharm.2019.05.033_bib13","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.phrs.2008.10.002","article-title":"The future (or lack of future) of personalized prescription in psychiatry","volume":"59","author":"de Leon","year":"2009","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/JCP.0b013e3182491383","article-title":"Evidence-based medicine versus personalized medicine: are they enemies?","volume":"32","author":"de Leon","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib15","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/JCP.0000000000000115","article-title":"False-negative studies may systematically contaminate the literature on the effects of inducers in neuropsychopharmacology: part II: focus on bipolar disorder","volume":"34","author":"de Leon","year":"2014","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.rpsm.2014.10.006","article-title":"The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part I: a summary of the current state for clinicians","volume":"8","author":"de Leon","year":"2015","journal-title":"Rev. Psiquiat\u00eda Salud Ment."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib17","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.rpsm.2014.10.005","article-title":"The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part II: pharmacological issues and further understanding","volume":"8","author":"de Leon","year":"2015","journal-title":"Rev. Psiquiat\u00eda Salud Ment."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib18","series-title":"Training Psychiatrists to Think like Pharmacologists","author":"de Leon","year":"2015"},{"key":"10.1016\/j.neuropharm.2019.05.033_bib19","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/JCP.0000000000000522","article-title":"Pharmacogenetic tests in psychiatry: from fear to failure to hype","volume":"36","author":"de Leon","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib20","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1080\/17425255.2017.1406920","article-title":"Have we successfully implemented CYP2D6 genotyping in psychiatry?","volume":"13","author":"de Leon","year":"2017","journal-title":"Expert Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1055\/s-0043-117891","article-title":"A critical commentary on the 2017 AGNP consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology","volume":"51","author":"de Leon","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.033_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/JCP.0000000000000924","article-title":"Why do you keep telling me that drug-drug interactions are important in psychopharmacology when I do not see them in my clinical practice? My failure to convince clinicians","volume":"39","author":"de Leon","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1176\/appi.psy.47.1.75","article-title":"Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19","volume":"47","author":"de Leon","year":"2006","journal-title":"Psychosomatics"},{"key":"10.1016\/j.neuropharm.2019.05.033_bib24","doi-asserted-by":"crossref","first-page":"450","DOI":"10.4088\/JCP.v58n1010b","article-title":"Risperidone and cytochrome P450 3A","volume":"58","author":"de Leon","year":"1997","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.033_bib25","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/01.jcp.0000085405.08426.73","article-title":"Serum antimuscarinic activity during clozapine treatment","volume":"23","author":"de Leon","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib26","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1176\/appi.psy.49.3.258","article-title":"A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: part I","volume":"49","author":"de Leon","year":"2008","journal-title":"Psychosomatics"},{"key":"10.1016\/j.neuropharm.2019.05.033_bib27","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1176\/appi.psy.49.4.347","article-title":"A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: part II","volume":"49","author":"de Leon","year":"2008","journal-title":"Psychosomatics"},{"key":"10.1016\/j.neuropharm.2019.05.033_bib28","article-title":"Pneumonia may be more frequent and have more fatal outcomes in clozapine than in other second-generation antipsychotics","author":"de Leon","year":"2019","journal-title":"World Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib29","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/01.jcp.0000106229.36344.67","article-title":"Postmortem clozapine levels","volume":"24","author":"de Leon","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib30","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1586\/17512433.2016.1112737","article-title":"What is needed to incorporate clinical pharmacogenetics tests into the practice of psychopharmacotherapy?","volume":"9","author":"de Leon","year":"2016","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4088\/JCP.v66n0103","article-title":"The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation","volume":"66","author":"de Leon","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.033_bib32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1017\/S1092852900020022","article-title":"DNA microarray technology in the clinical environment: the AmpliChip CYP450 test for CYP2D6 and CYP2C19 genotyping","volume":"14","author":"de Leon","year":"2009","journal-title":"CNS Spectr."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib33","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0893-133X(94)00069-C","article-title":"Treatment of polydipsia and hyponatremia in psychiatric patients. Can clozapine be a new option?","volume":"12","author":"de Leon","year":"1995","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.05.033_bib34","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0033-3182(10)70664-2","article-title":"The pharmacokinetics of paliperidone versus risperidone","volume":"51","author":"de Leon","year":"2010","journal-title":"Psychosomatics"},{"key":"10.1016\/j.neuropharm.2019.05.033_bib35","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/JCP.0000000000000926","article-title":"The effect of body weight changes on total plasma clozapine concentrations determined by applying a statistical model to the data from a double-blind trial","volume":"38","author":"Diaz","year":"2018","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib36","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2146\/ajhp070505","article-title":"Paliperidone: an improvement over risperidone?","volume":"65","author":"Dopheide","year":"2008","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"Suppl. 11","key":"10.1016\/j.neuropharm.2019.05.033_bib37","first-page":"12","article-title":"Pharmacokinetics and drug interactions: update for new antipsychotics","volume":"57","author":"Ereshefsky","year":"1996","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.033_bib38","doi-asserted-by":"crossref","DOI":"10.1007\/PL00005334","article-title":"Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4","volume":"359","author":"Fang","year":"1999","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib39","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00004714-199604000-00001","article-title":"Drug interactions, cardiac toxicity, and terfenadine: from bench to clinic?","volume":"16","author":"Flockhart","year":"1996","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib40","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/gim.2016.80","article-title":"Prediction of CYP2D6 phenotype from genotype across world populations","volume":"19","author":"Gaedigk","year":"2017","journal-title":"Genet. Med."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib41","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00228-007-0288-2","article-title":"Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans","volume":"63","author":"Ghotbi","year":"2007","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib42","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1055\/s-0031-1296207","article-title":"Plasma levels of clozapine and norclozapine in Mexican schizophrenia patients","volume":"61","author":"Gonz\u00e1lez-Esquivel","year":"2011","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.neuropharm.2019.05.033_bib43","doi-asserted-by":"crossref","first-page":"600","DOI":"10.4088\/JCP.v61n0810b","article-title":"Risperidone metabolism and the impact of being a cytochrome P450 2D6 ultrarapid metabolizer","volume":"61","author":"G\u00fczey","year":"2000","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.033_bib44","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/0091217415610313","article-title":"Elevated risperidone serum concentrations during acute inflammation, two cases","volume":"50","author":"Hefner","year":"2015","journal-title":"Int. J. Psychiatry Med."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib45","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s00213-015-3976-0","article-title":"Inflammation and psychotropic drugs: the relationship between C-reactive protein and antipsychotic drug levels","volume":"233","author":"Hefner","year":"2016","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2019.05.033_bib46","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/JCP.0b013e3181c17df0","article-title":"Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone","volume":"29","author":"Hendset","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib47","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"issue":"Suppl. 13","key":"10.1016\/j.neuropharm.2019.05.033_bib48","first-page":"17","article-title":"The pharmacokinetics of risperidone in humans: a summary","volume":"55","author":"Heykants","year":"1994","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.033_bib49","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/clpt.1993.146","article-title":"Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects","volume":"54","author":"Huang","year":"1993","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib50","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1176\/appi.ajp.160.6.1125","article-title":"Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic","volume":"160","author":"Kane","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.033_bib51","doi-asserted-by":"crossref","first-page":"279","DOI":"10.30773\/pi.2018.12.16","article-title":"Relationship between clozapine-induced electroencephalogram abnormalities and serum concentration of clozapine in Japanese patients with treatment-resistant schizophrenia","volume":"16","author":"Kikuchi","year":"2018","journal-title":"Psychiatr. Investig."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib52","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1258\/0004563053857798","article-title":"The cytochrome P450 CYP1A2 genetic polymorphisms *1F and *1D do not affect clozapine clearance in a group of schizophrenic patients","volume":"42","author":"Kootstra-Ros","year":"2005","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib53","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/jcph.366","article-title":"Population pharmacokinetic modeling and simulation to guide dose selection for RBP-7000, a new sustained-release formulation of risperidone","volume":"55","author":"Laffont","year":"2015","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib54","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s40263-015-0295-2","article-title":"The pharmacokinetics of second-generation long-acting injectable antipsychotics: limitations of monograph values","volume":"29","author":"Lee","year":"2015","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2019.05.033_bib55","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1055\/s-2007-973836","article-title":"A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels","volume":"40","author":"Leon","year":"2007","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.033_bib56","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2019.05.033_bib57","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0090-9556(25)08211-X","article-title":"Absorption, metabolism, and excretion of risperidone in humans","volume":"21","author":"Mannens","year":"1993","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.neuropharm.2019.05.033_bib58","article-title":"Unexpected falls during clozapine treatment explained by myoclonus","volume":"20","author":"McCollum","year":"2018","journal-title":"Prim. Care Companion CNS Disord."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib59","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nrg1428","article-title":"Pharmacogenetics \u2013 five decades of therapeutic lessons from genetic diversity","volume":"5","author":"Meyer","year":"2004","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib60","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.pnpbp.2009.08.009","article-title":"Short- and long-term effects on prolactin of risperidone and olanzapine treatments in children and adolescents","volume":"33","author":"Migliardi","year":"2009","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.033_bib61","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.rpsm.2015.11.003","article-title":"Spanish consensus on the risks and detection of antipsychotic drug-related hyperprolactinaemia","volume":"9","author":"Montejo","year":"2016","journal-title":"Rev. Psiquiat\u00eda Salud Ment."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib62","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00004850-200505000-00007","article-title":"An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels","volume":"20","author":"Ng","year":"2005","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib63","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nature21347","article-title":"Tracing the peopling of the world through genomics","volume":"541","author":"Nielsen","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2019.05.033_bib64","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1177\/00912700122010717","article-title":"Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations","volume":"41","author":"Olesen","year":"2001","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib65","first-page":"175","article-title":"Clozapine levels and caffeine","volume":"57","author":"Odom-White","year":"1996","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.033_bib66","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/YIC.0b013e32835ac9da","article-title":"Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia","volume":"28","author":"Rajkumar","year":"2013","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib67","doi-asserted-by":"crossref","first-page":"370","DOI":"10.5414\/CPP43370","article-title":"D2 dopamine receptor occupancy, risperidone plasma level and extrapyramidal motor symptoms in previously drug-free schizophrenic patients","volume":"43","author":"Regenthal","year":"2005","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib68","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/jcph.648","article-title":"Drug-drug interaction studies of paliperidone and divalproex sodium extended-release tablets in healthy participants and patients with psychiatric disorders","volume":"56","author":"Remmerie","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib69","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1097\/JCP.0b013e3182a4ea8f","article-title":"A case report that suggested that aspirin's effects on valproic acid metabolism may contribute to valproic acid's inducer effects on clozapine metabolism","volume":"33","author":"Riesselman","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib70","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.psym.2018.07.009","article-title":"Thirty years of both ignorance and clinical experience suggest that clozapine intoxication during co-occurring infections and inflammation may have higher morbidity and mortality than is currently believed","volume":"60","author":"Ruan","year":"2019","journal-title":"Psychosomatics"},{"key":"10.1016\/j.neuropharm.2019.05.033_bib71","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1177\/0091217417749799","article-title":"Two cases of high serum clozapine concentrations occurring during inflammation in Chinese patients","volume":"53","author":"Ruan","year":"2018","journal-title":"Int. J. Psychiatry Med."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib72","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/JCP.0000000000001018","article-title":"Clozapine metabolism in East Asians and Caucasians: a pilot exploration of the prevalence of poor metabolizers and a systematic review","volume":"39","author":"Ruan","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib73","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13089","article-title":"Maintenance dose conversion between oral risperidone and paliperidone palmitate 1 month: practical guidance based on pharmacokinetic simulations","volume":"72","author":"Russu","year":"2018","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib74","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ridd.2005.05.002","article-title":"Guidelines for the use of clozapine in individuals with developmental disabilities","volume":"27","author":"Sabaawi","year":"2006","journal-title":"Res. Dev. Disabil."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib75","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1046\/j.1365-2125.1998.00822.x","article-title":"Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance","volume":"46","author":"Schaber","year":"1998","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib76","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.euroneuro.2017.11.009","article-title":"Pharmacokinetics of risperidone in different application forms \u2013 comparing long-acting injectable and oral formulations","volume":"28","author":"Schoretsanitis","year":"2018","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib77","doi-asserted-by":"crossref","DOI":"10.1080\/17512433.2019.1617695","article-title":"A comprehensive review of the clinical utility of and a combined analysis of the clozapine\/norclozapine ratio in therapeutic drug monitoring for adult patients","author":"Schoretsanitis","year":"2019","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib78","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1080\/15622975.2018.1439595","article-title":"TDM in psychiatry and neurology: a comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians","volume":"19","author":"Schoretsanitis","year":"2018","journal-title":"World J. Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib79","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/17512433.2017.1345623","article-title":"A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone","volume":"10","author":"Schoretsanitis","year":"2017","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib80","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/17512433.2018.1478727","article-title":"A systematic review and combined analysis of therapeutic drug monitoring studies for oral paliperidone","volume":"11","author":"Schoretsanitis","year":"2018","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib81","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1080\/17512433.2018.1549489","article-title":"A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone","volume":"11","author":"Schoretsanitis","year":"2018","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib82","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1055\/a-0755-7692","article-title":"Studies of half-lives of long-acting antipsychotics are needed","volume":"52","author":"Schoretsanitis","year":"2019","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.033_bib83","doi-asserted-by":"crossref","first-page":"516","DOI":"10.2174\/138920010791636202","article-title":"Atypical antipsychotic metabolism and excretion","volume":"11","author":"Sheehan","year":"2010","journal-title":"Curr. Drug Metabol."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib84","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/00004714-199706000-00010","article-title":"Extrapyramidal symptoms in patients treated with risperidone","volume":"17","author":"Simpson","year":"1997","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib86","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cpt.1329","article-title":"\"Asian\" phenotype underestimates the genetic diversity of Asia yet overstates its impact on variability in drug disposition and pharmacodynamics","volume":"105","author":"Singh","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib85","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1021\/acs.jmedchem.8b01263","article-title":"Clearance in drug design","volume":"62","author":"Smith","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib87","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF02246543","article-title":"Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man","volume":"122","author":"Snoeck","year":"1995","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2019.05.033_bib88","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/00007691-200008000-00019","article-title":"Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate","volume":"22","author":"Spina","year":"2000","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib89","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00702-014-1300-5","article-title":"Clinical applications of CYP genotyping in psychiatry","volume":"122","author":"Spina","year":"2015","journal-title":"J. Neural. Transm. (Vienna)"},{"key":"10.1016\/j.neuropharm.2019.05.033_bib90","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1517\/17425255.2016.1154043","article-title":"Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics","volume":"12","author":"Spina","year":"2016","journal-title":"Expert Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib91","first-page":"CD009555","article-title":"Clozapine dose for schizophrenia","volume":"6","author":"Subramanian","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2019.05.033_bib92","series-title":"Serotonin in Antipsychotic Treatment: Mechanism and Clinical Practice","first-page":"277","article-title":"Clinical pharmacokinetics of risperidone","author":"Van Peer","year":"1996"},{"key":"10.1016\/j.neuropharm.2019.05.033_bib93","doi-asserted-by":"crossref","first-page":"282","DOI":"10.4088\/JCP.v62n0411","article-title":"Optimal dosing with risperidone: updated recommendations","volume":"62","author":"Williams","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.033_bib94","first-page":"1263","article-title":"Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes","volume":"29","author":"Yasui-Furukori","year":"2001","journal-title":"Drug Metab. Dispos."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390819301972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390819301972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:07:41Z","timestamp":1758438461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390819301972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":94,"alternative-id":["S0028390819301972"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.05.033","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Personalizing dosing of risperidone, paliperidone and clozapine using therapeutic drug monitoring and pharmacogenetics","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.05.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107656"}}